노바르티스 CEO 바산트 나라시만이 말하는 250년 역사의 기업 변혁
a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including ...
출처 기사
Acquired Podcast (United States) | Feb 16, 2026
Your votes count
No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.
번역 대기 중
번역 대기 중
번역 대기 중
번역 대기 중
번역 대기 중
💡 How This Works
- • Add Statements: Post claims or questions (10-500 characters)
- • Vote: Agree, Disagree, or Unsure on each statement
- • Respond: Add detailed pro/con responses with evidence
- • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement
Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.
Support us